BCYC
Bicycle Therapeutics plcstockNASDAQADR
bicycle therapeutics is a biotechnology company with big ambitions. we aim to revolutionise the pharmaceutical landscape with our disruptive technology and proprietary bicyclic peptide (bicycle®) product platform and to develop transformational new therapies for patients to improve future treatment options in oncology. bicycles, a new class of small molecular weight drug conjugates for oncology and other diseases, are designed to have superior targeting abilities and to be more efficacious and better tolerated than existing drug conjugate modalities. they combine the properties of several therapeutic entities in a single modality, exhibiting the affinity and selective pharmacology associated with antibodies; the distribution kinetics of small molecules, allowing rapid tumor penetration; and the "tuneable" pharmacokinetic half-life and renal clearance of peptides, sparing cytotoxin-payload derived liver and gastrointestinal toxicity. our unique ip is based on the work of scientific foun
| Period | Price | Date | Change | Beta |
|---|---|---|---|---|
| 1W | 3.45 | 2026-11-12 | -10.14% | 1.625 |
| 1M | 3.54 | 2026-10-19 | -12.31% | 1.679 |
| 3M | 4.14 | 2026-08-19 | -25.12% | 1.708 |
| 6M | 4.35 | 2026-05-19 | -28.74% | 1.296 |
| 1Y | 6.25 | 2025-11-19 | -50.40% | 1.711 |
| 2Y | 20.48 | 2024-11-19 | -84.86% | — |
| 5Y | 58.13 | 2021-11-19 | -94.67% | 1.118 |
Bicycle Therapeutics plc (NASDAQ:BCYC) stock price today is $3.10, and today's volume is 567,658. BCYC is down 3.125% today. The 30 day average volume is 421,750. BCYC market cap is $217.29M with 70.09M shares outstanding.